Literature DB >> 3196877

The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma.

J Pieters1, T Lindhout.   

Abstract

The antifactor Xa activities of heparin fractions are widely used as an ex vivo index of their antithrombotic efficacy. Its clinical meaning, however, remains speculative. In the study reported, we measured the effects of standard heparin, a synthetic pentasaccharide heparin (antifactor Xa activity only), and a low molecular weight heparin (LMWH) on factor Xa, factor Va, and thrombin generation in thromboplastin-activated plasma. We clearly demonstrated that the antifactor Xa activity of heparin contributed little in its anticoagulant activity. The inhibition of factor Va generation, dependent on the heparin antithrombin activity only, is of prime importance to the inhibition of thrombin generation in plasma. The inhibition of thrombin generation by the LMWH was comparable with that of standard heparin on the basis of their respective antithrombin specific activities, but not on the basis of their antifactor Xa activities.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3196877

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-Ch2Cl.

Authors:  X J Yang; M A Blajchman; S Craven; L M Smith; N Anvari; F A Ofosu
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

2.  Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C.

Authors:  J Petäjä; J A Fernández; A Gruber; J H Griffin
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

3.  Kinetics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor.

Authors:  T Lindhout; G Willems; R Blezer; H C Hemker
Journal:  Biochem J       Date:  1994-01-01       Impact factor: 3.857

4.  Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass.

Authors:  Ruwan Gunaratne; Shekhar Kumar; James W Frederiksen; Steven Stayrook; Jens L Lohrmann; Kay Perry; Kristin M Bompiani; Charlene V Chabata; Nabil K Thalji; Michelle D Ho; Gowthami Arepally; Rodney M Camire; Sriram Krishnaswamy; Bruce A Sullenger
Journal:  Nat Biotechnol       Date:  2018-06-04       Impact factor: 54.908

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.